Pharmaceutical Technology Europe-09-01-2008

Pharmaceutical Technology Europe
Spotlight

September 01, 2008

Researchers at Children's Hospital Boston (MA, USA) recently announced another group of stem cells that can produce cardiomyocytes (heart muscle cells). It seems hardly a month goes by without some kind of discovery in the fast-moving world of stem cells.

Pharmaceutical Technology Europe

The challenges of ineffective quality monitoring of complaints, investigations and adverse event reporting can lead to patient harm or death, product withdrawal, and negative financial and brand impact to the organization.

Pharmaceutical Technology Europe

September 01, 2008

It's back to school. Another summer has flown past and here we all meet again, ready to return to work and face the winter with renewed energies. Welcome back!

Pharmaceutical Technology Europe
Business

September 01, 2008

...some companies complained that what they received was not joint advice or combined advice but parallel advice, without coherence...

Pharmaceutical Technology Europe
Inside Out

September 01, 2008

All commercial sponsors want to maximize their profit and, with a population close to 500 million, the EU is an enormous potential marketplace that they simply cannot ignore!

Pharmaceutical Technology Europe
Inside Out

September 01, 2008

Pharmaceutical Technology Europe interviews Bruce Davis, Chairman of the International Society for Pharmaceutical Engineering Board (ISPE), the world's largest not-for-profit association dedicated to educating and advancing pharmaceutical manufacturing professionals and their industry.

Pharmaceutical Technology Europe

Near-infrared spectroscopy (NIR) is suitable for the analysis of pharmaceutical samples in various solid forms, and can be used for determining chemical properties (e.g., content of drug, water), as well as physical properties (e.g., particle size, tablet hardness).

Pharmaceutical Technology Europe
Business Talk

September 01, 2008

We have to make the politicians understand that if we don't take biotech seriously then tourism will be our premier industry in the future.

Pharmaceutical Technology Europe
Business

September 01, 2008

The Pharm Exec 50 report for 2008 accounts for prescription drug sales of more than $510 billion. Interestingly, except for Pfizer, GSK, Sanofi-Aventis (numbers one to three, respectively), and Watson (number 50), every company on the list showed positive growth last year, including some solid double-digit performances.

Pharmaceutical Technology Europe

Biotechnological developments have led to an increased number of recombinant proteins or antibodies in drug development that offer high potential in various diseases, such as cancer, growth disturbances and diabetes.

Pharmaceutical Technology Europe

Different chemistries and viscosities of HPMC can be combined to modulate release profile and, in some cases, result in a more robust formulation.

Pharmaceutical Technology Europe
Validation

September 01, 2008

The pharmaceutical industry is facing the perfect storm. Increasing healthcare costs, a changing regulatory environment and vigorous global competition coupled with the increasing complexity of small molecule and biotech drugs contributing to expensive discovery processes and clinical trials, as well as the resultant manufacturing challenges, all pose major threats to the industry.

Pharmaceutical Technology Europe
Analytical Equipment

September 01, 2008

Cascade impaction data characterizes all inhalation products, making the performance of impactors an important issue for the pharmaceutical sector.

Pharmaceutical Technology Europe
Surface Surgery

September 01, 2008

As counterfeiters become more cunning and technologically advanced, spotting their handiwork is increasingly difficult. Can surface analysis techniques be used to outwit them?

Pharmaceutical Technology Europe
Viewpoint

September 01, 2008

Pharmaceuticals used to be such a simple business when everyone knew their place.